NCG-M Mouse

NCG-M is a triple-immunodeficient NCG mouse expressing three human cytokines (IL3, GM-CSF (CSF2) and SCF (KITLG)). These cytokines support the stable engraftment of multiple lineages including myeloid cells and regulatory T cell populations after adoptive transfer of CD34+ hematopoietic stem cell. These animals can also be used as a mouse model of acute myeloid leukemia (AML). Origin The NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by introducing three human cytokine genes creating the NCG-SGM3. The strain was transferred to Charles River in 2022.